Osteoclast diseases

Microscopy Research and Technique

Volumn 61, Issue 6, 2003, Pages 514-532

  Helfrich, Miep H ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

ClC 7; Lrp5; OPG; Osteopetrosis; Paget's disease; Proton pump; RANK; Sequestosome 1

Indexed keywords

BONE; OSTEOBLASTS; PROTEINS;

CLC-7; LRP5; MINERALIZED BONE; OPG; OSTEOPETROSIS; PAGET DISEASE; PROTON PUMP; RANK; SEQUESTOSOME; SEQUESTOSOME-1;

DEFECTS;

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEINASE;

ALBERS SCHOENBERG DISEASE; BONE DISEASE; EMBRYO DEVELOPMENT; GENETIC DISORDER; HUMAN; OSTEOCLAST; OSTEOLYSIS; PAGET BONE DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PYKNODYSOSTOSIS; REVIEW;

EID: 0037766286     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jemt.10375     Document Type: Review

References (144)

1. Alper SL. 2002. Genetic diseases of acid-base transporters. Annu Rev Physiol 64:899-923.
2. Andersen PE, Bollerslev J. 1987. Heterogeneity of autosomal dominant osteopetrosis. Radiology 164:223-225.
3. Andrén L, Dymling L, Hogeman K, Weinberg B. 1962. Osteopetrosis acroosteolytica. Acta Chir Scand 124:496-507.
4. Beneton MNC, Harris S, Kanis JA. 1987. Paramyxovirus-like inclusions in two cases of pycnodysostosis. Metab Bone Dis Rel Res 8:211-217.
5. Bénichou OD, Laredo JD, de Vernejoul MC. 2000. Type II autosomal dominant osteopetrosis (Albers-Schönberg disease): clinical and radiological manifestations in 42 patients. Bone 26:87-93.
6. Bollerslev J, Mosekilde L. 1993. Autosomal dominant osteopetrosis. Clin Orthop 294:45-51.
7. Bollerslev J, Marks SC Jr, Pockwinse S, Kassem M, Brixen K, Steiniche T, Mosekilde L. 1993. Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis. Bone 14:865-869.
8. Borthwick KJ, Kandemir N, Topaloglu R, Kornak U, Bakkaloglu A, Yordam N, Ozen S, Mocan H, Shah GN, Sly WS, Karet FE. 2003. A phenocopy of CAII deficiency: a novel genetic explanation for inherited infantile osteopetrosis with distal renal tubular acidosis. J Med Gen 40:115-121.
9. Boyde A, Macconachie E, Reid SA, Mundy GR. 1986. Scanning electron microscopy in bone pathology: review of methods, potential and applications. Scan Electr Microsc IV:1537-1554.
10. Brömme D, Okamoto K, Wang BB, Biroc S. 1996. Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme. J Biol Chem 271:2126-2132.
11. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. 1998. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260-1268.
12. Campos-Xavier AB, Saraiva JM, Ribeiro LM, Munnich A, Cormier-Daire V. 2003. Chloride channel 7 (CLCN7) gene mutations in intermediate autosomal recessive osteopetrosis. Hum Genet 112:186-189.
13. Chalhoub N, Benachenhou N, Rajapurohitam V, Pata M, Ferron M, Frattini A, Villa A, Vacher J. 2003. Grey-lethal mutation induces severe malignant autosomal recessive osteoperosis in mouse and human. Nat Med 9:399-406.
14. Cheow HK, Steward CG, Grier DJ. 2001. Imaging of malignant infantile osteopetrosis before and after bone marrow transplantation. Pediatr Radiol 31:869-875.
15. Chong B, Hegde M, Fawkner M, Seidel J, Tuysuz B, Yuksel B, Coker M, Cassinelli H, Tau C, Love D, Cundy T. 2002. Mutations in the gene encoding osteoprotegerin cause idiopathic hyperphosphatasia. J.Bone Miner Res 17(Suppl1):S139 (abstract).
16. Cleiren E, Bénichou O, Van Hul E, Gram J, Bollerslev J, Singer FR, Beaverson K, Aledo A, Whyte MP, Yoneyama T, deVernejoul MC, Van Hul W. 2001. Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet 10:2861-2867.
17. Cody JD, Singer FR, Roodman GD, Otterund B, Lewis TB, Leppert M, Leach RJ. 1997. Genetic linkage of Paget disease of the bone to chromosome 18q. Am J Hum Genet 61:1117-1122.
18. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. 2001. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 276:20659-20672.
19. Cooper C, Shafheutle K, Dennison K, Guyer P, Barker DJ. 1999. The epidemiology of Pagets Disease in Britain: Is the prevalence decreasing? J Bone Miner Res 14:192-197.
20. Cournot G, Petrovic M, Trubert CL, Cormier C, Girault D, Fischer A, Garabedian M. 1993. Cultured circulating mononuclear cells from osteopetrotic infants express the osteoclast-associated vitronectin receptor and form multinucleated cells in response to 1,25-dihydroxyvitamin D3. J Bone Miner Res 8:61-70.
21. Cundy T, Wattie D, Busch S, Rutland M, Ibbertson HK. 1999. Paget's disease in New Zealand: is it changing? Bone 24:7S-9S.
22. Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, Mulley J, Love DR, Seidel J, Fawkner M, Banovic T, Callon KE, Grey AB, Reid IR, Middleton-Hardie CA, Cornish J. 2002. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 11:2119-2127.
23. Darozewska A, Hocking LJ, Langdahl B, McGuigan FEA, Fraser WD, Ralston SH. 2002. Osteoprotegerin alleles predispose to Paget's disease. Calcif Tissue Int 70:260 (abstract).
24. Dickson GR, Shirodria PV, Kanis JA, Beneton MN, Carr KE, Mollan RA. 1991. Familial expansile osteolysis: a morphological, histomorphometric and serological study. Bone 12:331-338.
25. Doherty TM, Uzui H, Fitzpatrick LA, Tripathi PV, Dunstan CR, Asotra K, Rajavashisth TB. 2002. Rationale for the role of osteoclast-like cells in arterial calcification. FASEB J 16:577-582.
26. Everts V, Aronson DC, Beertsen W. 1985. Phagocytosis of bone collagen by osteoclasts in two cases of pycnodysostosis. Calcif Tissue Int 37:25-31.
27. Everts V, Beertsen W, Schröder R. 1988. Effects of the proteinase inhibitors leupeptin and E-64 on osteoclastic bone resorption. Calcif Tissue Int 43:172-178.
28. Everts V, Hou WS, Rialland X, Tigchelaar W, Saftig P, Brömme D, Gelb BD, Beertsen W. 2003. Cathepsin K deficiency in pycnodysostosis results in accumulation of non-digested phagocytosed collagen in fibroblasts. Calcif Tissue Int (in press).
29. Feng X, Novack DV, Faccio R, Ory DS, Aya K, Boyer MI, McHugh KP, Ross FP, Teitelbaum SL. 2001. A Glanzmann's mutation in beta 3 integrin specifically impairs osteoclast function. J Clin Invest 107:1137-1144.
30. Flanagan AM, Horton MA, Dorey EL, Collins DA, Evely RS, Moseley JM, Firkin FC, Chambers TJ, Helfrich MH, Martin TJ. 1992. An assessment of the ability of human bone marrow cultures to generate osteoclasts. Int J Exp Pathol 73:387-401.
31. Flanagan AM, Sarma U, Steward CG, Vellodi A, Horton MA. 2000. Study of the nonresorptive phenotype of osteoclast-like cells from patients with malignant osteopetrosis: a new approach to investigating pathogenesis. J Bone Miner Res 15:352-360.
32. Flanagan AM, Massey HM, Wilson C, Vellodi A, Horton MA, Steward CG. 2002. Macrophage colony-stimulating factor and receptor activator NF-kappaB ligand fail to rescue osteoclast-poor human malignant infantile osteopetrosis in vitro. Bone 30:85-90.
33. Frattini A, Orchard PJ, Sobacchi C, Giliani S, Abinun M, Mattsson JP, Keeling DJ, Andersson AK, Wallbrandt P, Zecca L, Notarangelo LD, Vezzoni P, Villa A. 2000. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet 25:343-346.
34. Friedrichs WE, Reddy SV, Bruder JM, Cundy T, Cornish J, Singer FR, Roodman GD. 2002. Sequence analysis of measles virus nucleocapsid transccipts in patients with Paget's disease. J Bone Miner Res 17:145-151.
35. Fujita Y, Nakata K, Yasui N, Matsui Y, Kataoka E, Hiroshima K, Shiba RI, Ochi T. 2000. Novel mutations of the cathepsin K gene in patients with pycnodysostosis and their characterization. J Clin Endocrinol Metab 85:425-431.
36. Gelb BD, Edelson JG, Desnick RJ. 1995. Linkage of pycnodysostosis to chromosome 1q21 by homozygosity mapping. Nat Genet 10:235-237.
37. Gelb BD, Shi GP, Chapman HA, Desnick RJ. 1996. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273:1236-1238.
38. Gerritsen EJ, Vossen JM, van Loo IH, Hermans J, Helfrich MH, Griscelli C, Fischer A. 1994a. Autosomal recessive osteopetrosis: variability of findings at diagnosis and during the natural course. Pediatrics 93:247-253.
39. Gerritsen EJA, Vossen JM, Fasth A, Friedrich W, Morgan G, Padmos A, Vellodi A, Porras O, O'Meara A, Porta F. 1994b. Bone marrow transplantation for autosomal recessive osteopetrosis. A report from the Working Party on Inborn Errors of the European Bone Marrow Transplantation Group. J Pediatr 125:896-902.
40. Golob DS, McAlister WH, Mills BG, Fedde KN, Reinus WR, Teitelbaum SL, Beeki S, Whyte MP. 1996. Juvenile Paget disease: life-long features of a mildly affected young woman. J Bone Miner Res 11:132-142.
41. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Juppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML. 2001. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513-523.
42. Gowen M, Lazner F, Dodds R, Kapadia R, Feild J, Tavaria M, Bertoncello I, Drake F, Zavarselk S, Tellis I, Hertzog P, Debouck C, Kola I. 1999. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 14:1654-1663.
43. Harvey L, Gray T, Beneton MNC, Douglas DL, Kanis JA, Russell RGG. 1982. Ultrastructural features of the osteoclasts from Paget's disease of bone in relation to a viral aetiology. J Clin Pathol 35:771-779.
44. Haslam SI, Van Hul W, Morales-Piga A, Balemans W, San-Millan J, Nakatsuka KA, Haites NE, Ralston SH. 1998. Paget's disease of bone: Evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity. J Bone Miner Res 13:911-917.
45. Heaney C, Shalev H, Elbedour K, Carmi R, Staack JB, Sheffield VC, Beier DR. 1998. Human autosomal recessive osteopetrosis maps to 11q13, a position predicted by comparative mapping of the murine osteosclerosis (oc) mutation. Hum Mol Genet 7:1407-1410.
46. Helfrich MH, Gerritsen EJ. 2001. Formation of non-resorbing osteoclasts from peripheral blood mononuclear cells of patients with malignant juvenile osteopetrosis. Br J Haematol 112:64-68
47. Helfrich MH, Horton MA. 1999. Integrins and adhesion molecules. In: Seibel MJ, Robins SP, Bilezikan JP, editors. Dynamics of bone and cartilage metabolism. San Diego: Academic Press. p 111-125.
48. Helfrich MH, Aronson DC, Everts V, Mieremet RH, Gerritsen EJ, Eckhardt PG, Groot CG, Scherft JP. 1991. Morphologic features of bone in human osteopetrosis. Bone 12:411-419.
49. Helfrich MH, Nesbitt SA, Dorey EL, Horton MA. 1992. Rat osteoclasts adhere to a wide range of RGD (Arg-Gly-Asp) peptide-containing proteins, including the bone sialoproteins and fibronectin, via a β3 integrin. J Bone Miner Res 7:335-343.
50. Helfrich MH, Nesbitt SA, Lakkakorpi PT, Barnes MJ, Bodary SC, Shankar G, Mason WT, Mendrick DL, Väänänen HK, Horton MA. 1996. Beta 1 integrins and osteoclast function: involvement in collagen recognition and bone resorption. Bone 19:317-328.
51. Helfrich MH, Hobson RP, Grabowski PS, Zurbriggen A, Cosby SL, Dickson GR, Fraser WD, Ooi CG, Selby PL, Crisp AJ, Wallace RG, Kahn S, Ralston SH. 2000. A negative search for a paramyxoviral etiology of Paget's disease of bone: molecular, immunological, and ultrastructural studies in UK patients. J Bone Miner Res 15:2315-2329.
52. Hocking L, Slee F, Haslam SI, Cundy T, Nicholson G, Van Hul W, Ralston SH. 2000. Familial Paget's disease of bone: patterns of inheritance and frequency of linkage to chromosome 18q. Bone 26:577-580.
53. Hocking LJ, Herbert CA, Nicholls RK, Williams F, Bennett ST, Cundy T, Nicholson GC, Wuyts W, Van Hul W, Ralston SH. 2001. Genome-wide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. Am J Hum Genet 69:1055-1061.
54. Hocking LJ, Lucas GJ, Daroszewska A, Mangion J, Olavesen M, Cundy T, Nicholson GC, Ward L, Bennett ST, Wuyts W, Van Hul W, Ralston SH. 2002. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum Mol Genet 11:2735-2739.
55. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. 2000. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2-12.
56. Hou WS, Brömme D, Zhao Y, Mehler E, Dushey C, Weinstein H, Miranda CS, Fraga C, Greig F, Carey J, Rimoin DL, Desnick RJ, Gelb BD. 1999. Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis. J Clin Invest 103:731-738.
57. Hou WS, Li W, Keyszer G, Weber E, Levy R, Klein MJ, Gravallese EM, Goldring SR, Bromme D. 2002. Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum 46:663-674.
58. Hu PY, Ernst AR, Sly WS, Venta PJ, Skaggs LA, Tashian RE. 1994. Carbonic anhydrase II deficiency: single-base deletion in exon 7 is the predominant mutation in Caribbean Hispanic patients. Am J Hum Genet 54:602-608.
59. Hughes AE, Shearman AM, Weber JL, Barr RJ, Wallace RGH, Osterberg PH, Nevin NC, Mollan RAB. 1994. Genetic linkage of familial expansile osteolysis to chromosome 18q. Hum Mol Genet 3:359-361.
60. Hughes AE, Ralston SH, Marken J, Bell C, MacPherson H, Wallace RG, Van Hul W, Whyte MP, Nakatsuka K, Hovy L, Anderson DM. 2000. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 24:45-48.
61. Janssens K, Van Hul W. 2002. Molecular genetics of too much bone. Hum Mol Genet 11:2385-2393.
62. Janssens K, Gershoni-Baruch R, Van Hul E, Brik R, Guanabens N, Migone N, Verbruggen LA, Ralston SH, Bonduelle M, Van Maldergem L, Vanhoenacker F, Van Hul W. 2000. Localisation of the gene causing diaphyseal dysplasia Camurati-Engelmann to chromosome 19q13. J Med Genet 37:245-249.
63. Janssens K, Ten Dijke P, Ralston SH, Bergmann C, Van Hul W. 2003. Transforming growth factor-β1 mutations in Camurati-Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein. J Biol Chem 278:7718-7724.
64. Jentsch TJ, Stein V, Weinreich F, Zdebik AA. 2002. Molecular structure and physiological function of chloride channels. Physiol Rev 82:503-568.
65. Johnson MR, Polymeropoulos MH, Vos HL, Ortiz de Luna RI, Francomano CA. 1996. A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis. Genome Res 6:1050-1055.
66. Kato M, Patel MS, Levasseur R, Lobov I, Chang BH-J, Glass DA II, Hartmann C, Li L, Hwang T-H, Brayton CF, Lang RA, Karsenty G, Chan L. 2002. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157:303-314.
67. Kinoshita A, Saito T, Tomita H, Makita Y, Yoshida K, Ghadami M, Yamada K, Kondo S, Ikegawa S, Nishimura G, Fukushima Y, Nakagomi T, Saito H, Sugimoto T, Kamegaya M, Hisa K, Murray JC, Taniguchi N, Niikawa N, Yoshiura K. 2000. Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. Nat Genet 26:19-20.
68. Kornak U, Schulz A, Friedrich W, Uhlhaas S, Kremens B, Voit T, Hasan C, Bode U, Jentsch TJ, Kubisch C. 2000. Mutations in the a3 subunit of the vacuolar H(+)-ATPase cause infantile malignant osteopetrosis. Hum Mol Genet 9:2059-2063.
69. Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, Schulz A, Friedrich W, Delling G, Jentsch TJ. 2001. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104:205-215.
70. Krane SM. 2002. Genetic control of bone remodelling: insights from a rare disease. N Engl J Med 347:210-212.
71. Laitala T, Väänänen K. 1993. Proton channel part of vacuolar H(+)-ATPase and carbonic anhydrase II expression is stimulated in resorbing osteoclasts. J Bone Miner Res 8:119-126.
72. Laitala T, Väänänen HK. 1994. Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H(+)-ATPase. J Clin Invest 93:2311-2318.
73. Lajeunesse D, Busque L, Menard P, Brunette MG, Bonny Y. 1996. Demonstration of an osteoblast defect in two cases of human malignant osteopetrosis. Correction of the phenotype after bone marrow transplant. J Clin Invest 98:1835-1842.
74. Lakkakorpi PT, Horton MA, Helfrich MH, Karhukorpi EK, Väänänen HK. 1991. Vitronectin receptor has a role in bone resorption but does not mediate tight sealing zone attachment of osteoclasts to the bone surface. J Cell Biol 115:1179-1186.
75. Lark MW, Stroup GB, James IE, Dodds RA, Hwang SM, Blake SM, Lechowska BA, Hoffman SJ, Smith BR, Kapadia R, Liang X, Erhard K, Ru Y, Dong X, Marquis RW, Veber D, Gowen M. 2002. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat. Bone 30:746-753.
76. Laurin N, Brown JP, Lemainque A, Duchesne A, Huot D, Lacourciere Y, Drapeau G, Verreault J, Raymond V, Morissette J. 2001. Paget disease of bone: mapping of two loci at 5q35-qter and 5q31. Am J Hum Genet 69:528-543.
77. Laurin N, Brown JP, Morissette J, Raymond V. 2002. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 70:1582-1588.
78. Leach RJ, Singer FR, Roodman GD. 2001. The genetics of Paget's disease of the bone. J Clin Endocrinol Metab 86:24-28.
79. Li YP, Chen W, Stashenko P. 1996. Molecular cloning and characterization of a putative novel human osteoclast-specific 116-kDa vacuolar proton pump subunit. Biochem Biophys Res Commun 218:813-821.
80. Li YP, Chen W, Liang Y, Li E, Stashenko P. 1999. Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. Nat Genet 23:447-451.
81. Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, Morony S, Capparelli C, Van G, Kaufman S, van der HA, Itie A, Wakeham A, Khoo W, Sasaki T, Cao Z, Penninger JM, Paige CJ, Lacey DL, Dunstan CR, Boyle WJ, Goeddel DV, Mak TW. 1999. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 13:1015-1024.
82. Marks SC, Walker DG. 1976. Mammalian osteopetrosis. A model for studying cellular and humoral factors in bone resorption. In: Bourne G, editor. The biochemistry and physiology of bone. New York; Academic Press. p 227-301.
83. Marks SC, Seifert MF, Lane PW. 1985. Osteoselerosis, a recessive skeletal mutation on chromosome 19 in the mouse. J Hered 76:171-176.
84. Maroteaux P, Lamy M. 1962. Deux observations d'une affection osseuse condensante: la pycnodysostose. Arch Fr Paediatr 19:267-274.
85. McCauley LK. 2001. Transgenic mouse models of metabolic bone disease. Curr Opin Rheumatol 13:316-325.
86. McGowan NW, Walker EJ, MacPherson H, Ralston SH, Helfrich MH. 2001. Cytokine-activated endothelium recruits osteoclast precursors. Endocrinology 142:1678-1681.
87. McGowan N, MacPherson H, Janssens K, Van Hul W, Frith JC, Fraser WD, Ralston SH, Helfrich MH. 2003. A mutation affecting the latency associated peptide of TGFβ1 in Camurati-Engelmann disease enhances osteoclast formation in vitro. J Clin Endocrinol Metab 88:(in press).
88. McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, Feng X, Ross FP, Hynes RO, Teitelbaum SL. 2000. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 105:433-440.
89. Mee AP, Dixon JA, Hoyland JA, Davies M, Selby PL, Mawer EB. 1998. Detection of Canine Distemper Virus in 100% of Paget's disease samples by in situ-reverse transcriptase polymerase chain reaction. Bone 23:171-175.
90. Menaa C, Barsony J, Reddy SV, Cornish J, Cundy T, Roodman GD. 2000. 1,25-Dihydroxyvitamin D3 hypersensitivity of osteoclast precursors from patients with Paget's disease. J Bone Miner Res 15:228-236.
91. Michigami T, Kageyama T, Satomura K, Shima M, Yamaoka K, Nakayama M, Ozono K. 2002. Novel mutations in the a3 subunit of vacuolar H(+)-adenosine triphosphatase in a Japanese patient with infantile malignant osteopetrosis. Bone 30:436-439.
92. Mills BG, Singer FR. 1976. Nuclear inclusions in Paget's disease of bone. Science 194:201-202.
93. Mills BG, Singer FR, Weiner LP, Suffin SC, Stabile E, Holst P. 1984. Evidence for both respiratory syncytial virus and measles virus antigens in the osteoclasts of patients with Paget's disease of bone. Clin Orthop Rel Res 183:303-311.
94. Mills BG, Yabe H, Singer F. 1988. Osteoclasts in human osteopetrosis contain viral-nucleocapsid-like nuclear inclusions. J Bone Miner Res 3:101-106.
95. Nakatsuka K, Nishizawa Y, Ralston SH. 2003. Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. J Bone Miner Res 18 (in press).
96. Neale SD, Smith R, Wass JA, Athanasou NA. 2000. Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL. Bone 27:409-416.
97. Nesbitt SA, Horton MA. 1997. Trafficking of matrix collagens through bone-resorbing osteoclasts. Science 276:266-269.
98. Nishi T, Forgac M. 2002. The vacuolar (H+)-ATPases: nature's most versatile proton pumps. Nat Rev Mol Cell Biol 3:94-103.
99. Paget J. 1876. On a form of chronic inflammation of bones (Osteitis Deformans). Med-Chir Trans ix:37-63.
100. Ralston SH, Helfrich MH, Hobson RP, Pennington TH. 1997. Does Paget's disease really have a viral aetiology? J Bone Miner Res 12:863-864.
101. Rebel A, Malkani K, Basle M, Bregeon C. 1974. Particularités ultrastructurales des osteoclasts de la maladie de Paget. Rev Rhum Mal Osteoartic 41:767-771.
102. Rebel A, Basle M, Pouplard A, Malkani K, Filmon R, Lepatezour A. 1980. Bone tissue in Paget's disease of bone. Ultrastructure and immunocytology. Arth Rheum 23:1104-1114.
103. Reddy SV, Menaa C, Singer FR, Cundy T, Cornish J, Whyte MP, Roodman GD. 1999. Measles virus nucleocapsid transcript expression is not restricted to the osteoclast lineage in patients with Paget's disease of bone. Exp Hematol 27:1528-1532.
104. Reddy SV, Kurihara N, Menaa C, Landucci G, Forthal D, Koop BA, Windle JJ, Roodman GD. 2001a. Osteoclasts formed by measles virus-infected osteoclast precursors from hCD46 transgenic mice express characteristics of pagetic osteoclasts. Endocrinology 142:2898-2905.
105. Reddy SV, Kurihara N, Menaa C, Roodman GD. 2001b. Paget's disease of bone: a disease of the osteoclast. Rev Endocr Metab Disord 2:195-201.
106. Rima BK. 1999. Paramyxoviruses and chronic human diseases. Bone 24:23S-26S.
107. Rima BK, Gassen U, Helfrich MH, Ralston SH. 2002. The pro and con of measles virus in Paget's disease: con. J Bone Miner Res 17:2290-2292.
108. Rodan SB, Rodan GA. 1997. Integrin function in osteoclasts. J Endocrinol 154:S47-S56.
109. Roth DE, Venta PJ, Tashian RE, Sly WS. 1992. Molecular basis of human carbonic anhydrase II deficiency. Proc Natl Acad Sci USA 89:1804-1808.
110. Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, Moritz JD, Schu P, von Figura K. 1998. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 95:13453-13458.
111. Saito T, Kinoshita A, Yoshiura K, Makita Y, Wakui K, Honke K, Niikawa N, Taniguchi N. 2001. Domain-specific mutations of a transforming growth factor (TGF)-beta 1 latency-associated peptide cause Camurati-Engelmann disease because of the formation of a constitutively active form of TGF-beta 1. J Biol Chem 276:11469-11472.
112. Salo J, Lehenkari P, Mulari M, Metsikko K, Väänänen HK. 1997. Removal of osteoclast bone resorption products by transcytosis. Science 276:270-273.
113. Sanz L, Sanchez P, Lallena MJ, Diaz-Meco MT, Moscat J. 1999. The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation. EMBO J 18:3044-3053.
114. Sanz L, Diaz-Meco MT, Nakano H, Moscat J. 2000. The atypical PKC-interacting protein p62 channels NF-kappaB activation by the IL-1-TRAF6 pathway. EMBO J 19:1576-1586.
115. Schoppet M, Preissner KT, Hofbauer LC. 2002. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 22:549-553.
116. Scimeca JC, Franchi A, Trojani C, Parrinello H, Grosgeorge J, Robert C, Jaillon O, Poirier C, Gaudray P, Carle GF. 2000. The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants. Bone 26:207-213.
117. Selby P, Davie M, Ralston S, Stone M. 2002. Guidelines on the management of Paget's disease of bone. Bone 31:366-373.
118. Shapiro F, Key LL, Anast C. 1988. Variable osteoclast appearance in human infantile osteopetrosis. Calcif Tissue Int 43:67-76.
119. Siris ES, Ottman R, Flaster E, Kelsey JL. 1991. Familial aggregation of Paget's disease of bone. J Bone Miner Res 6:495-500.
120. Sly WS, Hewett-Emmett D, Whyte MP, Yu YS, Tashian RE. 1983. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci USA 80:2752-2756.
121. Sobacchi C, Frattini A, Orchard P, Porras O, Tezcan I, Andolina M, Babul-Hirji R, Baric I, Canham N, Chitayat D, Dupuis-Girod S, Ellis I, Etzioni A, Fasth A, Fisher A, Gerritsen B, Gulino V, Horwitz E, Klamroth V, Lanino E, Mirolo M, Musio A, Matthijs G, Nonomaya S, Notarangelo LD, Ochs HD, Superti FA, Valiaho J, van Hove JL, Vihinen M, Vujic D, Vezzoni P, Villa A. 2001. The mutational spectrum of human malignant autosomal recessive osteopetrosis. Hum Mol Genet 10:1767-1773.
122. Stenbeck G. 2002. Formation and function of the ruffled border in osteoclasts. Cell Dev Biol 13:285-292.
123. Stroup GB, Lark MW, Veber DF, Bhattacharyya A, Blake S, Dare LC, Erhard KF, Hoffman SJ, James IE, Marquis RW, Ru Y, Vasko-Moser JA, Smith BR, Tomaszek T, Gowen M. 2001. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Miner Res 16:1739-1746.
124. Taranta A, Migliaccio S, Recchi I, Caniglia M, Luciani M, De Rossi G, Dionisi-Vici C, Pinto RM, Francalanci P, Boldrini R, Lanino E, Dini G, Morreale G, Ralston SH, Villa A, Vezzoni P, Del Principe D, Cassiani F, Palumbo G, Teti A. 2003. Genotype-phenotype relationship in ATP6i-dependent autosomal recessive osteopetrosis. Am J Pathol 162:57-68.
125. Teti A, Migliaccio S, Taranta A, Bernardini S, De Rossi G, Luciani M, Iacobini M, De Felice L, Boldrini R, Bosman C, Corsi A, Bianco P. 1999. Mechanisms of osteoclast dysfunction in human osteopetrosis: abnormal osteoclastogenesis and lack of osteoclast-specific adhesion structures. J Bone Miner Res 14:2107-2117.
126. Theill LE, Boyle WJ, Penninger JM. 2002. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 20:795-823.
127. Tiegs RD, Lohse CM, Wollan PC, Melton LJ 2000. Long-term trends in the incidence of Paget's disease of bone. Bone 27:423-427.
128. Tilyard MW, Gardner RJ, Milligan L, Cleary TA, Stewart RD. 1982. A probable linkage between familial Paget's disease and the HLA loci. Aust NZ J Med 12:498-500.
129. Toyomura T, Oka T, Yamaguchi C, Wada Y, Futai M. 2000. Three subunit a isoforms of mouse vacuolar H(+)-ATPase. Preferential expression of the a3 isoform during osteoclast differentiation. J Biol Chem 275:8760-8765.
130. Väänänen HK, Horton M. 1995. The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure. J Cell Sci 108:2729-2732.
131. Väänänen HK, Zhao H, Mulari M, Halleen JM. 2001. The cell biology of osteoclast function. J Cell Sci 113:377-381.
132. Vadlamudi RK, Joung I, Strominger JL, Shin J. 1996. p62, a phosphotyrosine-independent ligand of the SH2 domain of p561ck, belongs to a new class of ubiquitin-binding proteins. J Biol Chem 271:20235-20237.
133. Van Hul E, Gram J, Bollerslev J, Van Wesenbeeck L, Mathysen D, Andersen PE, Vanhoenacker F, Van Hul W. 2002. Localization of the gene causing autosomal dominant osteopetrosis type I to chromosome 11q12-13. J Bone Miner Res 17:1111-1117.
134. Van Slyke MA, Marks SC. 1987. Failure of normal osteoclasts to resorb calcified cartilage from osteosclerotic (oc/oc) mice in vitro. Bone 8:39-44.
135. Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Bénichou O, Scopelliti D, Key L, Renton T, Bartels C, Gong Y, Warmen ML, De Vernejoul MC, Bollerslev J, Van Hul W. 2003. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 72:763-771.
136. Wallace RGH, Barr RJ, Osterberg PH, Mollan RAB. 1989. Familial expansile osteolysis. Clin Orthop Rel Res 248:265-277.
137. Whyte, MP. 1993. Carbonic anhydrase II deficiency. Clin Orthop 52-63.
138. Whyte MP, Hughes AE. 2002. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res 17:26-29.
139. Whyte MP, Leelawattana R, Reddy SV, Roodman GD. 1996. Absence of paramyxo virus transcripts in juvenile Paget bone disease. J Bone Miner Res 11:1041.
140. Whyte MP, Mills BG, Reinus WR, Podgornik MN, Roodman GD, Gannon FH, Eddy MC, McAlister WH. 2000. Expansile skeletal hyperphosphatasia: a new familial metabolic bone disease. J Bone Miner Res 15:2330-2344.
141. Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, Mumm S. 2002. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 347:175-184.
142. Wuyts W, Van Wesenbeeck L, Morales-Piga A, Ralston S, Hocking L, Vanhoenacker F, Westhovens R, Verbruggen L, Anderson D, Hughes A, Van Hul W. 2001. Evaluation of the role of RANK and OPG genes in Paget's disease of bone. Bone 28:104-107.
143. Yarah N, Fisgin T, Duru F, Kara A. 2003. Osteopetrosis and Glanzmann's thrombasthenia in a child. Ann Hematol 82:254-256.
144. Zatloukal K, Stumptner C, Fuchsbichler A, Heid H, Schnoelzer M, Kenner L, Kleinert R, Prinz M, Aguzzi A, Denk H. 2002. p62 is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol 160:255-263.